New drug combo aims to make stem cell transplants safer for sickle cell patients
NCT ID NCT06145282
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new combination of drugs (briquilimab, abatacept, and alemtuzumab) plus low-dose radiation to prepare people with sickle cell disease for a stem cell transplant from a half-matched family donor. The goal is to reduce serious side effects like graft-versus-host disease and organ damage. Six participants aged 16 and older will be followed for 5 years to see if the transplant is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- briquilimab, abatacept, alemtuzumab, and radiation
- What this could lead to
- If it works, this could make stem cell transplants safer and more available for people with sickle cell disease, even those with organ damage.
- What could go wrong
- This is a very early, small trial with only 6 participants. The new drug combo may not work as hoped, and there are serious risks like graft failure or severe graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Co-Designed support help parents embrace sickle cell care?
- Can community hospitals in zambia master severe disease care?
- A Pocket-Sized coach for sickle cell: can an app turn Pill-Taking into a habit?
- Can a phone app keep teens on track with sickle cell treatment?
- A common amino acid may calm sickle cell pain crises — a trial puts it to the test
- A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease